David Bond

29PUBLICATIONS
223CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 10, 2026
Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

|Feb 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Jia Ruan, David A Bond, Bijal Shah

|Feb 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Feb 04, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Zachary J Arnold, Jordan Lundberg, Tracy Wiczer

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Dec 09, 2025
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.

Aseel Alsouqi, Ying Huang, Beth Christian

Pageof 5

Frequent Collaborators

10 joint publications

Narendranath Epperla

9 joint publications

Yazeed Sawalha

7 joint publications

Reem Karmali

5 joint publications

Robert Baiocchi